[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"congenital-melanocytic-nevus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:congenital-melanocytic-nevus":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100439233","early-phase-1-sadbe-for-congenital-melanocytic-nevi-100439233",false,"NCT04999631","SADBE for Congenital Melanocytic Nevi","Neoadjuvant Squaric Acid Dibutylester Treatment of Melanocytes in Congenital Melanocytic Nevi","Inclusion Criteria:\n\n* 18 years of age or older.\n* Subject or parents willing and able to give informed consent, and assent as appropriate.\n* Patients who have a clinical diagnosis of CMN with plans for elective non-urgent excision of part or all of their nevus, with nevus surface area of \\> 6 cm2.\n\nExclusion Criteria:\n\n* Immunosuppressive therapy with glucocorticoid or other systemic immunosuppressant within 4 weeks of recruitment (except for inhaled corticosteroids for asthma).\n* History of malignancy.\n* History of organ transplantation.\n* Known immunosuppressive disease, including infection with HIV.\n* Severe medical comorbidities (diabetes mellitus requiring insulin, CHF of any severity, MI, CVA, or TIA within 3 months of screening visit, unstable angina pectoris, oxygen-dependent severe pulmonary disease)\n* Subject is currently enrolled in another investigational device or drug trial(s), or subject has received other investigational agent(s) within 28 days of baseline visit.\n* Subjects who have known hypersensitivity to SADBE or any of its components.\n* Any condition judged by the investigator to cause this clinical trial to be detrimental to the patient.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","A study to evaluate the safety and efficacy topical squaric acid dibutylester (SADBE) for the neoadjuvant treatment of congenital melanocytic nevi (CMN).",[26],"Congenital Melanocytic Nevus","NOT_YET_RECRUITING","2026-05-19",{"date":30,"type":31},"2026-05-22","ACTUAL",{"date":33,"type":20},"2027-01-01",{"date":35,"type":20},"2030-06-01",{"name":37,"class":38},"Massachusetts General Hospital","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":50,"conditions":51,"keywords":54,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100562613","precision-medicine-for-lgcmn-and-melanoma-2-100562613","NCT06605443","Precision Medicine for L\u002FGCMN and Melanoma 2","Precision Medicine for L\u002FGCMN and Melanoma 1 (Precis-mel 2)","Precis-mel 2","Inclusion Criteria:\n\n* Be over 18 years old\n* Have a histopathological confirmed melanoma diagnosis (stage II, III or IV AJCC)\n\nExclusion Criteria:\n\n* Not signing the informed consent form\n* Present other cancers or chronic diseases (such as diabetes, asthma, etc.), which may affect the volatile organic compound profiles",{"count":48,"type":20},100,"OBSERVATIONAL","The primary objective is to evaluate the possibility of using minimally and non-invasive technologies (skin patch and breath analyzer) based on the detection of volatile organic compounds (VOCs) for the early identification of metastases. The secondary objective is to evaluate the usability of these technologies in the follow up of high-risk melanoma patients.",[52,53,26],"Melanoma (Skin Cancer)","Nevi and Melanomas",[55,56,57,58,59,60,61,62],"Volatilomics","Breath analyzer","Skin patch","Melanoma","L\u002FGCMN","Liquid biopsy","cfDNA","Non-invasive diagnostics","RECRUITING","2025-02-25",{"date":66,"type":31},"2025-02-27",{"date":68,"type":31},"2025-01-01",{"date":70,"type":20},"2026-12-01",{"name":72,"class":38},"Fundacion Clinic per a la Recerca Biomédica",3]